201 filings
8-K
SAVA
Cassava Sciences Inc
15 Apr 24
Redemption Date Announced for Warrants
4:01pm
8-K
SAVA
Cassava Sciences Inc
28 Feb 24
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
9:22am
8-K
SAVA
Cassava Sciences Inc
7 Feb 24
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
9:20am
8-K
SAVA
Cassava Sciences Inc
3 Jan 24
Entry into a Material Definitive Agreement
9:10am
8-K
SAVA
Cassava Sciences Inc
12 Dec 23
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
9:19am
8-K
m43bk3qe5pmra8 qld24
11 Dec 23
Cassava Sciences Appoints
4:18pm
8-K
qksjlw gqnscghio3cg
7 Nov 23
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
9:08am
8-K
318t12sl
13 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:17pm
8-K
gg2a6
3 Aug 23
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
9:12am
8-K
5cc0xt3n
5 Jul 23
Other Events
9:25am
8-K
cjjw7fstv5d4lchz 2ff
8 May 23
Submission of Matters to a Vote of Security Holders
4:03pm
8-K
hu08psg1 78z4e
1 May 23
Entry into a Material Definitive Agreement
5:26pm
8-K
zq5e s5skgeecnj
1 May 23
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
9:05am
8-K
gw35te
16 Mar 23
Departure of Directors or Certain Officers
5:36pm
8-K
8w2enqd
10 Mar 23
Other Events
3:08pm
8-K
qknkyv9
28 Feb 23
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
9:25am
8-K
cce672g6hsa48
24 Jan 23
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
4:30pm
8-K
2hwonwwx4 4n1
22 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:56pm
8-K
9el6vix8kkkv
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
8-K
vbe4rn6
7 Nov 22
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
9:09am